US FDA approves a form of Lu-177 … but this is NOT for prostate cancer

Some readers may have noticed that, late last week, the US Food and Drug Administration (FDA) approved a product known as lutetium Lu-177 dotatate or Lutathera for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

We want to be very clear for readers that while this is a product that employs the radiopharmaceutical activity of Lu-177 to treat a specific (and rare) type of cancer, it is not the same as the types of product that combine the activity of Lu-177 with the targeting capabilities of prostate-specific membrane antigen (PSMA) and that are in clinical trials for the treatment of progressive and metastatic forms of prostate cancer. For information about those types of product, please see recent articles by Allen Edel on this site that you can find here and here.

One Response

  1. The premise for 177Lu-PSMA-based radioligand therapy is demonstration of PSMA expression in the cancer lesions as with PSMA-based PET/CT. I am skeptical for high expression of PSMA for neuroendocrine variants of prostate cancer. Otherwise metastatic, casytration-resistant prostate cancer has a high expression of PSMA and might be a good target for 177Lu-PSMA-67 radioligand therapy.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: